Author Archive: George Goodno

George Goodno

George is the Director of State Policy Communications at BIO and enjoys the opportunity to advocate for and educate audiences about the positive societal and economic impact of the bioscience industry. Another great aspect of his job is getting to work with BIO’s broad network of state bioscience associations to help advance legislative and regulatory initiatives that will continue to improve this high-skill, high-wage industry. In his spare time, he enjoys running, skiing, hiking, gardening, and most of all, spending time with his awesome wife and two daughters.

Follow him on Twitter @ggoodno

 

Latest Posts

PTAB Ruling Proves Medical Innovation Under Attack

US_Patent_And_Trademark_Office

There’s more evidence today that the IPR system needs to be fixed. PTAB ruled on Friday that under current rules, hedge fund managers are free to manipulate the system by shorting drug company stocks and then challenging their patents. Here’s what the panel said: “Profit is at the heart of nearly every patent and nearly every inter partes review. As such, an economic motive for challenging a patent claim does not itself raise abuse of Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO on CNBC: IPR System Weakens Medical Innovation

ron-cohen_115x76

Last night Ron Cohen, M.D., CEO of Acorda Therapeutics and BIO’s board chair, appeared on CNBC’s Fast Money where he discussed our industries concerns’ with the U.S. Patent and Trademark Office’s patent challenge system known as Inter Partes Review (IPR). Dr. Cohen concisely explained this complicated and rapidly evolving issue and made clear why Congress must quickly address abuses to the IPR system within current Patent reform legislation. Regrettably, this system that was designed by Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Here are the Facts about the IPR Kill Rate

US_Patent_And_Trademark_Office

FiercePhrma recently ran an article repeating a dubious analysis of the crisis caused by the rapidly increasing number of biopharma related inter partes reviews (IPR) currently within the United States Patent and Trademark Office (PTO). It is troubling that in a single breath Ronny Gal both dismissed the biopharmaceutical industry’s concerns with the PTO’s IPR process and acknowledged that limited data prevents any firm conclusions about the potential impact of IPR on biotech innovation. If Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

102 Organizations Urge Congress to Maintain a Strong Patent System and Protect Innovation

US Capitol Building

A diverse group of more than 100 national and state-based advocacy organizations have united to urge Congress to preserve important patent protections that incentivize biopharmaceutical research necessary to innovate and develop new cures and treatments for serious diseases. In a letter sent to the Hill this week, these patient advocates asked Congress to amend the Innovation Act (H.R. 9) to preserve the highly-detailed and sophisticated systems designed by Hatch-Waxman and BPCIA and avoid weakening the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Seventy Nine House Members Express Concern with H.R. 9

Vote No on HR 9

House leaders made the decision earlier this month to remove patent reform legislation from the schedule for the remaining days before the August recess. While a vote is expected to occur sometime in September, House Majority Leader Kevin McCarthy made the decision to review and address many of the concerns that have been voiced by an array of industries that require the value of dependable and enforceable patents. In the words of Representative McCarthy, “I Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,